{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-270377","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.828268+00:00","generated_at":"2026-06-08T22:42:39.041685+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023","bullets":["SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).","Pharmacokinetics: dose-proportional exposure, linear elimination, no target-mediated drug disposition; supports every-three-week dosing.","SNS-101 achieved dose levels >10x higher than a competitor VISTA antibody that was halted due to CRS, suggesting best-in-class potential.","Expected data readouts: initial combo safety/PK data Q1 2024, topline monotherapy Q2 2024, topline combo later in 2024.","Late-breaking poster at SITC 2023 on Nov 4; data supports conditionally active VISTA-blocking approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-270377","json":"https://secwatch.observer/filing/0001193125-23-270377.json","markdown":"https://secwatch.observer/filing/0001193125-23-270377.md","text":"https://secwatch.observer/filing/0001193125-23-270377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/0001193125-23-270377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/d556062d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:42:39.041685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}